1. Food and Drug Administration Center for Drug Evaluation and Research. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products – General Considerations (2003); http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM389370.pdf; [http://www.fda.gov/ohrms/dockets/ac/03/briefing/3995B1 07 GFI-BioAvail-BioEquiv.pdf].
2. Food and Drug Administration. Therapeutic Equivalence of Generic Drugs: Letter to Health Practitioners (1998) [Accessed Jan. 21, 2010]; http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplication-ANDAGenerics/ucm073182.htm.
3. P. Meredith, Clin. Ther., 25, 2875 – 2890 (2003).
4. European Medicines Agency (EMA) (2014); http://www.ema.europa.eu/docs/en GB/document library/Scientific.
5. P. Kwan and M. J. Brodie, N. Engl. J. Med., 342, 314 – 319 (2000).